Clinical Trials Logo

Clinical Trial Summary

The present observational study has been designed to understand the dynamics of viral clearance amongst patients with confirmed monkeypox, by quantifying monkeypox viral load in different specimens trough time, to better inform decision-making about patient management and isolation guidelines. Also, an immune analysis will be performed in a subset of individuals to describe humoral and cellular responses to monkeypox.


Clinical Trial Description

Starting in early May 2022 a large number of cases of Monkeypox have been reported in non-endemic countries. Although initial cases appeared to be linked to travel, the majority of subsequent cases appear to have no travel associated risk factors and these cases have predominantly occurred amongst Men who have Sex with Men (MSM) suggesting autochthonous transmission associated with sexual networks. Monkeypox is known to be transmitted by close contact with skin lesions of infected individuals and/or via droplets. It is known that the virus can be detected from skin lesions, in blood, in throat swabs and on occasion urine samples. There is limited information as to whether the virus can be detected or persist in other sites including semen. Serial virological monitoring has been conducted in a small number of individuals and demonstrates that prolonged shedding for at least 2-3 weeks appears to be relatively common. To help control the current outbreak health authorities have used a number of strategies including identifying and isolating cases of monkeypox combined with contact tracing and limited use of ring-vaccination strategies. Because the number of cases seen outside of endemic areas has previously been limited, there is inadequate data to guide decision-making about the duration of isolation, but this is critical to the management of the current outbreak. The present observational study has been designed to understand the dynamics of viral clearance amongst patients with confirmed monkeypox, by quantifying monkeypox viral load in different specimens trough time, to better inform decision-making about patient management and isolation guidelines. Also, an immune analysis will be performed in a subset of individuals to describe humoral and cellular responses to monkeypox. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05476744
Study type Observational [Patient Registry]
Source Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Contact
Status Completed
Phase
Start date June 28, 2022
Completion date March 30, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05512949 - Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine Phase 2
Completed NCT05976100 - Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years Phase 1
Recruiting NCT05988203 - A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines Phase 1
Recruiting NCT05567939 - Clinical, Virological, Immunological, Psychosocial and Epidemiological Consequences of Human Monkeypox Virus (ProMPX)
Active, not recruiting NCT05562323 - Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
Recruiting NCT05534984 - Study of Tecovirimat for Human Monkeypox Virus Phase 3
Recruiting NCT05879965 - Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
Completed NCT03745131 - Cohort Study of Healthcare Workers Receiving Imvanex®
Recruiting NCT05559099 - Tecovirimat for Treatment of Monkeypox Virus Phase 2
Completed NCT05846243 - Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years Phase 2/Phase 3
Not yet recruiting NCT05965427 - Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
Not yet recruiting NCT05629299 - Pilot Study to Detect Monkey Pox Virus in Sperm: POXSPERM N/A
Recruiting NCT05654883 - New York City Observational Study of Mpox Immunity
Completed NCT05762523 - Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years Phase 1
Recruiting NCT05597735 - Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease Phase 3
Recruiting NCT05734508 - Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC Phase 4
Active, not recruiting NCT05740982 - A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox Phase 2
Recruiting NCT06045923 - Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
Recruiting NCT05947786 - Mpox Paediatric and Adolescent Clinical Study
Recruiting NCT06291259 - Mpox Prospective Observational Cohort Study